Individualised cancer vaccine - Immunovative Therapies

Drug Profile

Individualised cancer vaccine - Immunovative Therapies

Alternative Names: AlloVax; CRCL-AlloVax

Latest Information Update: 21 Jul 2016

Price : $50

At a glance

  • Originator Immunovative Therapies
  • Developer Immunovative Inc; Immunovative Therapies
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatocellular carcinoma
  • Phase I/II Head and neck cancer
  • Preclinical Haematological malignancies

Most Recent Events

  • 21 Jul 2016 Individualised cancer vaccine is still in preclinical studies for Haematological malignancies in USA and Israel
  • 01 Jul 2016 Phase-II clinical trials in Hepatocellular carcinoma (Late-stage disease, Second-line therapy or greater) in Thailand (Intradermal) (NCT02409524)
  • 11 Dec 2015 Immunovative Therapies plans a phase II trial for Head and neck cancer (Late-stage disease, Metastatic disease) in Thailand (NCT02624999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top